When to Hold Irbesartan Due to Renal or Cardiovascular Risks

Absolute Contraindications Requiring Immediate Discontinuation

• The American Heart Association recommends holding irbesartan in patients with severe bilateral renal artery stenosis due to risk of acute renal failure 1
• Angiotensin II is necessary for maintaining GFR when renal perfusion is compromised, as stated by the American College of Cardiology 2
• The European Society of Cardiology advises against using irbesartan if the patient has a history of angioedema with ARBs 1

Temporary Holds - Clinical Situations Requiring Suspension

• The American College of Cardiology suggests holding irbesartan during states of significant volume depletion as angiotensin II is necessary for maintaining GFR 2
• The European Heart Journal recommends suspending irbesartan during severe dehydration, aggressive diuresis, or symptomatic hypotension 2
• Temporary discontinuation of irbesartan is advised if acute renal failure develops, according to the American Heart Association 2
• A rise in serum creatinine >30% from baseline warrants holding the medication, as stated by the American College of Cardiology 2

Monitoring Parameters to Guide Holding Decisions

• The European Society of Cardiology recommends checking serum creatinine and potassium within 2-4 weeks after initiation or dose increase, although this specific guideline is from Praxis Medical Insights, a similar recommendation is made by the American Heart Association 2
• An initial rise in creatinine of 10-20% is expected and acceptable, representing hemodynamic changes rather than kidney injury, as stated by the American College of Cardiology 2
• Progressive increases beyond 30% warrant discontinuation, according to the American Heart Association 2

Combination Therapy Restrictions

• The American Heart Association explicitly advises against combining irbesartan with ACE inhibitors or direct renin inhibitors due to increased risk of hyperkalemia, hypotension, and renal dysfunction 1, 5
• This combination is not recommended by current guidelines from the European Society of Cardiology 5

Special Populations

• The American College of Cardiology recommends that end-stage renal disease patients on dialysis can continue irbesartan but should avoid polyacrylonitrile dialysis membranes due to risk of anaphylactoid reactions 2